Emphysema

1,218,722views

Emphysema

COMP 4

COMP 4

Staphylococcus epidermidis
Staphylococcus aureus
Staphylococcus saprophyticus
Streptococcus viridans
Streptococcus pneumoniae
Streptococcus pyogenes (Group A Strep)
Streptococcus agalactiae (Group B Strep)
Listeria monocytogenes
Corynebacterium diphtheriae (Diphtheria)
Nocardia
Actinomyces israelii
Pseudomonas aeruginosa
Klebsiella pneumoniae
Legionella pneumophila (Legionnaires disease and Pontiac fever)
Yersinia pestis (Plague)
Neisseria meningitidis
Neisseria gonorrhoeae
Moraxella catarrhalis
Francisella tularensis (Tularemia)
Bordetella pertussis (Whooping cough)
Haemophilus influenzae
Mycobacterium tuberculosis (Tuberculosis)
Mycoplasma pneumoniae
Chlamydia pneumoniae
Chlamydia trachomatis
Borrelia burgdorferi (Lyme disease)
Coxiella burnetii (Q fever)
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Viral structure and functions
Herpes simplex virus
Adenovirus
Parvovirus B19
Coxsackievirus
Poliovirus
Rhinovirus
Hepatitis A and Hepatitis E virus
Influenza virus
Respiratory syncytial virus
Human parainfluenza viruses
Rubella virus
Acute respiratory distress syndrome
Emphysema
Asthma
Bronchiectasis
Chronic bronchitis
Cystic fibrosis
Alpha 1-antitrypsin deficiency
Restrictive lung diseases
Idiopathic pulmonary fibrosis
Pneumonia
Obstructive lung diseases: Pathology review
Tuberculosis: Pathology review
Pneumonia: Pathology review
Restrictive lung diseases: Pathology review
Lung volumes and capacities
Pressure-volume loops
Changes in pressure-volume loops
Acute respiratory distress syndrome: Clinical
Respiratory distress syndrome: Pathology review
Upper respiratory tract infection
Bacterial epiglottitis
Bacillus anthracis (Anthrax)
Vaccinations
Yellow fever virus
Vaccinations: Clinical
Renal tubular acidosis
Minimal change disease
Diabetic nephropathy
Focal segmental glomerulosclerosis (NORD)
Amyloidosis
Lupus nephritis
Membranous nephropathy
Membranoproliferative glomerulonephritis
Poststreptococcal glomerulonephritis
IgA nephropathy (NORD)
Rapidly progressive glomerulonephritis
Alport syndrome
Kidney stones
Hydronephrosis
Acute pyelonephritis
Chronic pyelonephritis
Renal azotemia
Prerenal azotemia
Postrenal azotemia
Renal cortical necrosis
Renal papillary necrosis
Chronic kidney disease
Medullary sponge kidney
Medullary cystic kidney disease
Renal cell carcinoma
Nephroblastoma (Wilms tumor)
Beckwith-Wiedemann syndrome
Angiomyolipoma
WAGR syndrome
Posterior urethral valves
Hypospadias and epispadias
Vesicoureteral reflux
Bladder exstrophy
Urinary incontinence
Neurogenic bladder
Lower urinary tract infection
Transitional cell carcinoma
Non-urothelial bladder cancers
Renal failure: Pathology review
Nephritic syndromes: Pathology review
Nephrotic syndromes: Pathology review
Urinary tract infections: Pathology review
Urinary incontinence: Pathology review
Kidney stones: Pathology review
Renal and urinary tract masses: Pathology review
Blastomycosis
Histoplasmosis
Mucormycosis
Aspergillus fumigatus
Cryptococcus neoformans
Candida
Schistosomes
Croup
Enterococcus
Clostridium difficile (Pseudomembranous colitis)
Bacillus cereus (Food poisoning)
Escherichia coli
Proteus mirabilis
Vibrio cholerae (Cholera)
Brucella
Cytomegalovirus
Poxvirus (Smallpox and Molluscum contagiosum)
Mumps virus
Measles virus
Dengue virus
Ebola virus
Hantavirus
Coccidioidomycosis and paracoccidioidomycosis
Pneumocystis jirovecii (Pneumocystis pneumonia)
Cryptosporidium
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Azoles
Antihistamines for allergies
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Pulmonary corticosteroids and mast cell inhibitors
Bronchodilators: Leukotriene antagonists and methylxanthines
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Lung cancer and mesothelioma: Pathology review
Sleep apnea
Pulmonary edema
Mesothelioma
Superior vena cava syndrome
Lung cancer
Pancoast tumor
Laryngitis
Sinusitis
Retropharyngeal and peritonsillar abscesses
Allergic rhinitis
Benign prostatic hyperplasia
Prostate cancer
Potter sequence
Prostate disorders and cancer: Pathology review
Testicular and scrotal conditions: Pathology review

Flashcards

Emphysema

0 of 13 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 5 complete

Start
A 62-year-old woman comes to the PA due to dyspnea and a productive cough for the past several months. Past medical history is significant for hypertension. The patient has a 42-pack-year smoking history. She has tried multiple times to quit smoking by herself, but these attempts have been unsuccessful.Temperature is 37.0°C (98.6°F), pulse is 88/min, respirations are 14/min, blood pressure is 132/84 mm Hg, and oxygen saturation is 95% on room air. Physical examination reveals diffuse bilateral wheezes and rales. Pulmonary function testing (PFT) is performed, and the diagnosis of chronic obstructive pulmonary disease (COPD) is confirmed. The patient is given a medication that works primarily as a high-affinity partial agonist for the α4β2 nicotinic acetylcholine receptor. Which of the following medications was most likely given?

Transcript

Watch video only

Emphysema means “inflate or swell”, which makes sense because in the lungs of people with emphysema, the alveolar air sacs, which are the thin walled air spaces at the ends of the airways where oxygen and carbon dioxide are exchanged, become damaged or destroyed.

The alveoli permanently enlarge and lose elasticity, and as a result, individuals with emphysema typically have difficulty with exhaling, which depends heavily on the ability of lungs to recoil like elastic bands.

Emphysema’s actually lumped under the umbrella of chronic obstructive pulmonary disease (or COPD), along with chronic bronchitis.

The two differ in that chronic bronchitis is defined by clinical features, like the productive cough, whereas emphysema is defined by structural changes, mainly enlargement of the air spaces.

That being said, they almost always coexist, probably because they share the same major cause—smoking.

With COPD, the airways become obstructed, the lungs don’t empty properly, and that leaves air trapped inside the lungs.

For that reason, the maximum amount of air people with COPD can breath out in a single breath, known as the FVC, or forced vital capacity, is lower.

This reduction is especially noticeable in the first second of air breathed out in a single breath, called FEV1forced expiratory volume (in one second), which typically is reduced even more than the FVC.

A useful metric therefore is the FEV1 to FVC ratio, which, since the FEV1 goes down even more than FVC, causes the FEV1 to FVC ratio to go down as well.

Alright so say normally your FVC is 5 L, and your FEV1 is 4 L, your FEV1 to FVC ratio would end up being 80%.

Now, someone with COPD’s FVC might be 4 L instead, which is lower than normal, but the volume of air that he or she can expire in the first second is only 2 L, so not only are both these values lower, but their ratio is lower as well—and this is a hallmark of COPD.

All that had to do with air breathed out right? Conversely, for air going in, the TLC, or total lung capacity, which is the maximum volume of air that can be taken in or inspired into the lungs, is actually often often higher because of the air trapping.

Alright, so emphysema is a form of COPD, that’s based on structural changes in the lung, specifically a destruction of the alveoli.

Normally, though oxygen flows out of the alveoli and into the blood while carbon dioxide makes the reverse commute, but when the lung tissue is exposed to irritants like cigarette smoke, it triggers an inflammatory reaction that upsets the delicate alveolar walls and affects the flow of gases.

Inflammatory reactions attract various immune cells which release inflammatory chemicals like leukotriene B4, IL-8, and TNF alpha, as well as proteases, like elastases and collagenases.

These proteases break down key structural proteins in the connective tissue layer like collagen, as well as elastin, which is a protein that gives the tissue elasticity, and this leads to the problems seen in emphysema.

In healthy lungs, during exhalation, air whizzes through the airways with high velocity, creating a low pressure environment in the airway.

This is due to the Bernoulli principle, where, as a fluid—which includes air—moves at higher velocity, it must have lower pressure. Now this lower pressure tends to pull the tiny airway inward.

Strong healthy airway walls full of elastin can withstand that pressure and don’t collapse; they hold the airway open and allow air to fully escape during exhalation.

With emphysema though, that elastin’s lost, which makes the airway walls weak and allow that low pressure system to pull the walls inward and collapse during exhalation.

This ultimately leads to air-trapping because the collapsed airway traps a tiny bit of air distal to the point of collapse.

Also, this loss of elastin makes the lungs more compliant, meaning that when air blows into them, they easily expand and then hold onto that air instead of expelling it during exhalation, and so the lungs start to look like large thin plastic bags.

The loss of elastin also leads to a breakdown of the thin alveolar walls called septa.

Without these walls, neighboring alveoli coalesce into larger and larger air spaces, which means the surface area available for gas exchange is reduced (relative to the expanding volume), which affects oxygen and carbon dioxide levels.

This process all happens in the acinus, which is the endings of the lung airways where those clusters of alveoli are located.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease" American Journal of Respiratory and Critical Care Medicine (2013)
  6. "Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology" European Respiratory Journal (2005)
  7. "Screening for Chronic Obstructive Pulmonary Disease" JAMA (2016)
  8. "Endocarditis" JAMA (2018)
  9. "Infective endocarditis" The Lancet (2016)
  10. "Endocardite infectieuse. Épidémiologie, physiopathologie et anatomopathologie" La Presse Médicale (2019)